SHANGHAI FOSUN PHARMACEUTICAL Aktie

 

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

LEHI, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ: NATR) (“Nature's Sunshine” or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the pricing of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the “Selling Stockholder”). The shares of common stock are being sold at a price of $12.00 per share. The offering is expected to close on June 27, 2025, subject to customary closing conditions....

LEHI, Utah, June 25, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ: NATR) (“Nature's Sunshine” or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the launch of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the “Selling Stockholder”)....

PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Monday said that they have partnered to develop TEV-56278.Teva's TEV-56278 ut......

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278 Partnership leverages......

FOSUN PHARMA (02196.HK)(600196.SH) announced that it repurchased a total of 800,300 shares of the company on the Shanghai Stock Exchange today (6th), with the price per share ranging from RMB24.92 to RMB25.14, involving a total of approximately RMB19.9988 million. ~AASTOCKS Financial NewsWebsite: www.aastocks.com...

FOSUN PHARMA (02196.HK) opened up 2.27% today (30th) and once surged by 10.3% to a peak of HKD16.5. It last traded at HKD16.38, up 9.49%, on a volume of 30.4045 million shares, involving HKD488 million.Shanghai Fosun Pharmaceutical Industrial, a subsidiary of Fosun Pharmaceutical, has received approval from China's National ......

Stock│Forecast for Percentage of Revenue from Export to US in 2025COWELL (01415.HK)│30%ASMPT(00522.HK)│15%BYD ELECTRONIC (00285.HK)│around 25-30%.KLN (00636.HK)│15-20%AAC TECH (02018.HK)│12%FOSUN PHARMA (02196.HK)│11%SUNNY OPTICAL (02382.HK)│9%Q TECH (01478.HK)│<1%CHERVON ......

FOSUN PHARMA (02196.HK) announced a strategic partnership with Saudi Arabia’s Fakeeh Care Group, an integrated healthcare group, to jointly promote biologics, CAR-T cell therapies, and other cutting-edge treatments in Saudi Arabia, accelerating local medical innovation. Guo Guangchang, Chairman of Fosun International, expr......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY SHANGHAI, March 25, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"or "the Group"; Stock Code: 600196.SH, 02196.HK), a leading global......

Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval...

Bringing New Hope to Chinese Dialysis Patients with Hyperphosphatemia SHANGHAI, Feb. 26, 2025 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) announced that its holding subsidiary, Shanghai Fosun Pharmaceutical Industrial......

FOSUN PHARMA (02196.HK) recently released internally its self-developed PharmAID decision agent platform, which is currently constructing a full lifecycle intelligent decision-making network covering innovative R&D scenarios, according to FOSUN PHARMA. The platform deeply integrates the world's leading foundation model t......

Chinese biopharmaceutical company JIUYUAN GENE (02566.HK) announced the details of its offering. It proposed to offer 45.3988 million shares globally, of which about 10% will be offered in Hong Kong and about 90% will be offered internationally. The offer price ranges from $11.48 to $12.56 per share.The entry fee is $2,537.33 fo......

Revenue Exceed RMB30.9 Billion with R&D Expenditure RMB3.9 Billion Continuing to Consolidate its Dominant Position In The fields of Breast Cancer and Lung Cancer SHANGHAI, Oct. 29, 2024 /PRNewswire/ -- On October 29, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the......

Breakthroughs for Innovative Products Going Overseas with Global Operation Capabilities Continuing to Strengthen SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- On August 27, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH; 02196.HK),......

Das Instrument 08HH CNE100001M79 SHANG.FOS.PHARM.GR.H YC 1 EQUITY wird ex Dividende/Zinsen gehandelt am 26.07.2024 The instrument 08HH CNE100001M79 SHANG.FOS.PHARM.GR.H YC 1 EQUITY has its ex-dividend/interest day on 26.07.2024...

Das Instrument 08HH CNE100001M79 SHANG.FOS.PHARM.GR.H YC 1 EQUITY wird cum Dividende/Zinsen gehandelt am 25.07.2024 und ex Dividende/Zinsen am 26.07.2024 The instrument 08HH CNE100001M79 SHANG.FOS.PHARM.GR.H YC 1 EQUITY has its pre-dividend/interest day on 25.07.2024 and its ex-dividend/interest day on 26.07.2024...